What's Happening?
Panome Bio has introduced an exposomics service platform that profiles chemical exposures in biological samples. This service combines Discovery Exposomics, powered by MassID for untargeted LC/MS data analysis, and Targeted Exposomics, which quantifies
235 priority chemicals. The platform aims to address the challenge of profiling chemical exposures, which are estimated to drive 70-90% of chronic disease risk. By capturing this dimension, exposomics offers a new lens for understanding disease variability and drug response, potentially improving clinical trial outcomes and patient stratification.
Why It's Important?
The ability to profile chemical exposures at scale could transform our understanding of disease etiology and treatment response. As environmental exposures significantly impact health, this service provides a critical tool for identifying previously unmeasured determinants of health outcomes. By integrating exposomics with other omics sciences, researchers can gain a comprehensive view of how chemical exposures influence disease pathways and treatment efficacy. This advancement could lead to more personalized medicine approaches and improved public health strategies.
What's Next?
Panome Bio plans to expand its exposomics capabilities and integrate them with metabolomics, proteomics, and transcriptomics. This comprehensive approach could enhance drug development by identifying chemical exposure-related confounders in clinical trials. Future research may focus on refining exposomics methodologies and exploring their applications in diverse populations. As the field evolves, exposomics could become a standard component of precision medicine, offering insights into the complex interactions between genetics, environment, and health.
